HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.